fda - Page 1 | CARLAT PUBLISHING

PTSD 101: Prazosin or SSRI?

September 17, 2024

Chris Aiken, MD and Kellie Newsome, PMHNP

Should we follow the FDA and give SSRIs, or venture off-label with the fabled prazosin?

MDMA: What Went Wrong Part 2

June 17, 2024

Chris Aiken, MD and Kellie Newsome, PMHNP

Did boundary violations sink MDMA-assisted therapy, or was there something more? In part II of our series, we look at what else went wrong.

MDMA: What Went Wrong Part 1

June 10, 2024

Chris Aiken, MD

Did boundary violations sink MDMA assisted psychotherapy? We explore the reasons behind the FDA panel’s rejection of this psychedelic therapy.

Clinical Update

Off-Label Strategies for Common Psychiatric Conditions

June 1, 2024

Chris Aiken, MD

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Dr. Aiken has no financial relationships with companies related to this material.

Five disorders where going off-label has advantages over the FDA-approved route.

Research Update

Efficacy of Auvelity for Major Depression

April 1, 2024

Nina Chandler, DNP, APRN, PMHNP-BC

Nina Chandler, DNP, APRN, PMHNP-BC. Dr. Chandler has no financial relationships with companies related to this material.

A dextromethorphan-bupropion combo tablet shows promise in treating major depression. The FDA recognized its potential in 2019, so stay tuned for more updates on this novel treatment.

Clinical Update

Six Recent Disappointments in Psychiatric Research

February 1, 2024

Chris Aiken, MD

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Dr. Aiken has no financial relationships with companies related to this material.

Find out where standard therapies like cariprazine and esketamine have failed in recent trials, along with novel medications like minocycline, zuranolone, pimavanserin, and NAC.

Psychopharm Commandment 7B: Red Flags & Controlled Meds

April 10, 2023

Chris Aiken, MD and Kellie Newsome, PMHNP

More red flags to watch for when prescribing controls, and how to manage them in practice.

The Adderall Shortage

January 22, 2023

Chris Aiken, MD and Kellie Newsome, PMHNP

Adderall is in short supply, and the backlog is having a domino effect on other stimulants. Find out why, and how long it will last.

RESEARCH UPDATE

Less Sleep Correlated with Dementia

October 1, 2022

Talya Shahal, MD.

Talya Shahal, MD. Dr. Shahal, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

This study supports an association between short sleep duration in middle life and an increasedrisk of dementia.

In Brief: Meds in the Fast Lane

November 5, 2021

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC.

In the last five years, more psychotropics have gained approval through the FDA’s expedited pathways than the slow and cautious routes we’ve grown used to. These “fast-track” and “breakthrough therapy” approvals allow drugs to enter the market on the basis of more efficient (ie, smaller) clinical trials.